AU2005319141B8 - Compositions of influenza viral proteins and methods of use thereof - Google Patents

Compositions of influenza viral proteins and methods of use thereof Download PDF

Info

Publication number
AU2005319141B8
AU2005319141B8 AU2005319141A AU2005319141A AU2005319141B8 AU 2005319141 B8 AU2005319141 B8 AU 2005319141B8 AU 2005319141 A AU2005319141 A AU 2005319141A AU 2005319141 A AU2005319141 A AU 2005319141A AU 2005319141 B8 AU2005319141 B8 AU 2005319141B8
Authority
AU
Australia
Prior art keywords
seq
protein
influenza
fusion protein
flagellin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005319141A
Other languages
English (en)
Other versions
AU2005319141B2 (en
AU2005319141A1 (en
Inventor
Duane D. Hewitt
William F. Mcdonald
Valerian Nakaar
Thomas J. Powell
Langzhou Song
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vaxinnate Corp
Original Assignee
Vaxinnate Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxinnate Corp filed Critical Vaxinnate Corp
Publication of AU2005319141A1 publication Critical patent/AU2005319141A1/en
Priority to AU2010200048A priority Critical patent/AU2010200048A1/en
Application granted granted Critical
Publication of AU2005319141B2 publication Critical patent/AU2005319141B2/en
Publication of AU2005319141B8 publication Critical patent/AU2005319141B8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2005319141A 2004-12-21 2005-12-21 Compositions of influenza viral proteins and methods of use thereof Ceased AU2005319141B8 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2010200048A AU2010200048A1 (en) 2004-12-21 2010-01-07 Compositions of influenza viral proteins and methods of use thereof

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US63825404P 2004-12-21 2004-12-21
US63835004P 2004-12-21 2004-12-21
US60/638,254 2004-12-21
US60/638,350 2004-12-21
US64506705P 2005-01-19 2005-01-19
US60/645,067 2005-01-19
US65320705P 2005-02-15 2005-02-15
US60/653,207 2005-02-15
US66687805P 2005-03-31 2005-03-31
US60/666,878 2005-03-31
US68207705P 2005-05-18 2005-05-18
US60/682,077 2005-05-18
US74120205P 2005-11-30 2005-11-30
US60/741,202 2005-11-30
PCT/US2005/046662 WO2006069262A2 (en) 2004-12-21 2005-12-21 Compositions of influenza viral proteins and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2010200048A Division AU2010200048A1 (en) 2004-12-21 2010-01-07 Compositions of influenza viral proteins and methods of use thereof

Publications (3)

Publication Number Publication Date
AU2005319141A1 AU2005319141A1 (en) 2006-06-29
AU2005319141B2 AU2005319141B2 (en) 2010-02-18
AU2005319141B8 true AU2005319141B8 (en) 2010-03-18

Family

ID=36272492

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2005319141A Ceased AU2005319141B8 (en) 2004-12-21 2005-12-21 Compositions of influenza viral proteins and methods of use thereof
AU2010200048A Abandoned AU2010200048A1 (en) 2004-12-21 2010-01-07 Compositions of influenza viral proteins and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2010200048A Abandoned AU2010200048A1 (en) 2004-12-21 2010-01-07 Compositions of influenza viral proteins and methods of use thereof

Country Status (9)

Country Link
EP (1) EP1831259A2 (enExample)
JP (1) JP2008524261A (enExample)
AU (2) AU2005319141B8 (enExample)
BR (1) BRPI0519705A2 (enExample)
CA (1) CA2593746A1 (enExample)
MX (1) MX2007007586A (enExample)
NZ (1) NZ556004A (enExample)
SG (1) SG160424A1 (enExample)
WO (1) WO2006069262A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR052195A1 (es) 2005-01-19 2007-03-07 Vaxinnate Corp Composiciones de patrones moleculares asociados a patogenos en metodos de uso
ES2555544T3 (es) 2006-03-07 2016-01-04 Vaxinnate Corporation Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
EP2012829A4 (en) * 2006-04-24 2010-04-21 Protelix Inc PROCESS FOR PRODUCING VIRAL VACCINE AND THERAPEUTIC PEPTIDE ANTIGENS
EP2517723B1 (en) * 2006-09-18 2019-11-06 The Board of Trustees of The University of Arkansas Compositions and methods of enhancing immune responses
EP1925318A1 (en) * 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
WO2008157419A2 (en) * 2007-06-13 2008-12-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic peptides of influenza virus
WO2009016639A2 (en) 2007-08-02 2009-02-05 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope influenza vaccines
GB0720250D0 (en) 2007-10-17 2007-11-28 Univ Edinburgh Immunogenic compositions containing escherichia coli h7 flagella and methods of use thereof
EP2223934B1 (en) * 2007-11-14 2012-10-03 Institute Of Microbiology, Chinese Academy Of Sciences Polypeptides for inhibiting influenza virus infection
SG190562A1 (en) 2008-04-18 2013-06-28 Vaxinnate Corp Deletion mutants of flagellin and methods of use
WO2010115229A1 (en) 2009-04-09 2010-10-14 The University Of Melbourne Immunogenic composition and uses thereof
MX348663B (es) * 2009-09-08 2017-05-26 Inst Tecnologico Estudios Superiores Monterrey Proceso de producción de una vacuna recombinante, dicha vacuna expresable en cepas de escherichia coli y su uso para combatir la influenza a h1ni1 brote 2009.
US20130095130A1 (en) * 2010-01-06 2013-04-18 Vaxinnate Corporation Methods and Compositions for Providing Protective Immunity in the Elderly
CN102811734B (zh) 2010-01-21 2016-02-10 阿肯色大学评议会 增强免疫应答的疫苗载体和方法
CN103118709A (zh) * 2010-03-26 2013-05-22 新兴产品开发盖瑟斯堡有限公司 流感病毒基质2蛋白的胞外域、其表达系统和应用
GB201009273D0 (en) * 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
CA2811957C (en) 2010-09-22 2019-04-16 The University Of Melbourne Soluble tlr2 moiety for use in the treatment or prevention of respiratory conditions associated with infectious agents
WO2012114323A1 (en) 2011-02-22 2012-08-30 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
WO2014070848A1 (en) * 2012-11-05 2014-05-08 Georgia State University Research Foundation Universal influenza vaccine based on heterologous multiple m2e proteins
RU2571944C1 (ru) * 2014-10-17 2015-12-27 Общество с ограниченной ответственностью "НТфарма" Противогриппозная вакцина широкого спектра действия против птичьего гриппа а на основе эктодомена белка м2
IL275360B2 (en) 2017-12-21 2023-10-01 Axelia Oncology Pty Ltd Optimal compounds
NZ783377A (en) 2019-06-26 2026-03-27 Ena Respiratory Pty Ltd Pegylated novel molecules for agonising tlr2
AU2022338350A1 (en) * 2021-09-02 2024-02-29 Ena Respiratory Pty Ltd Formulation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014956A1 (en) * 2002-08-12 2004-02-19 The Council Of The Queensland Institute Of Medical Research Novel immunogenic lipopeptides comprising t-helper and b-cell epitopes
WO2004080403A2 (en) * 2003-03-07 2004-09-23 Merck & Co. Inc. Influenza virus vaccine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014956A1 (en) * 2002-08-12 2004-02-19 The Council Of The Queensland Institute Of Medical Research Novel immunogenic lipopeptides comprising t-helper and b-cell epitopes
WO2004080403A2 (en) * 2003-03-07 2004-09-23 Merck & Co. Inc. Influenza virus vaccine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FAN, J. et al, Vaccine, 2004, Vol. 22, pages 2993-3003 *
HEINEN, P. P. et al, Journal of General Virology, 2002, Vol. 83, pages 1851-1859 *
ZENG, W. et al, Vaccine, 2000, Vol. 18, pages 1031-1039 *

Also Published As

Publication number Publication date
CA2593746A1 (en) 2006-06-29
BRPI0519705A2 (pt) 2009-03-10
WO2006069262A2 (en) 2006-06-29
JP2008524261A (ja) 2008-07-10
EP1831259A2 (en) 2007-09-12
SG160424A1 (en) 2010-04-29
MX2007007586A (es) 2007-12-10
WO2006069262A3 (en) 2007-02-01
AU2010200048A1 (en) 2010-01-28
AU2005319141B2 (en) 2010-02-18
NZ556004A (en) 2010-05-28
AU2005319141A1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
AU2005319141B2 (en) Compositions of influenza viral proteins and methods of use thereof
Huleatt et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin
US20090162400A1 (en) Compositions of influenza viral proteins and methods of use thereof
US9200042B2 (en) Flagellin fusion proteins
AU2009236585B2 (en) Deletion mutants of flagellin and methods of use
EP2069503B1 (en) Papaya mosaic virus-based vaccines for influenza
CN106661091B (zh) 流行性感冒病毒疫苗及其用途
AU2014273173B2 (en) Influenza virus vaccines and uses thereof
US20120052082A1 (en) Cross-protective influenza vaccine
KR20200113226A (ko) 인플루엔자 바이러스 백신 및 이의 용도
JP7167088B2 (ja) インフルエンザウイルスワクチンおよびその使用
CN101087808A (zh) 流行性感冒病毒蛋白质的组合物及其使用方法

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 24, NO 7, PAGE(S) 778 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME VAXINNATE CORPORATION, APPLICATION NO. 2005319141, UNDER INID (71) CORRECT THE APPLICANT NAME TO VAXINNATE CORPORATION

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired